Practice Obligations Clause Samples

Practice Obligations. The Practice staff agree to: Teach students according to the appropriate Study Guide (Appendix 1) and within the spirit of the Good Teaching Practice Guidelines (Appendix 2) in consideration of payments made (Appendix 4). Provide adequate, maintained teaching space; access to suitable ICT; basic equipment required for clinical work; safe storage for students' belongings; a typical case mix of patients. Nominate a suitably qualified and experienced doctor with overall responsibility for teaching students (The Responsible Tutor). This individual should complete any training for teaching and assessment required by the Centre for Medical Education. Ensure that all staff welcome students and, in principle, support the training of students by the Practice. Cooperate with quality management measures and monitoring arrangements as defined by the Centre for Medical Education. Typically these include the use of student evaluation questionnaires, attendance at meetings organised by the Centre for Medical Education, engagement in Equality and Diversity training and possibly visits to Practices by Centre for Medical Education staff. Have in place insurance arrangements deemed suitable by the Practice insurer (in accordance with the recommendations in Appendix 3). Make patients aware that students receive training at the Practice. Patients must be assured that they will only see students with their consent, and will not be disadvantaged by refusing to have medical students involved in their care. Continually seek to improve their knowledge base by reading current literature, and, where appropriate, being involved in research, thus facilitating high quality teaching. Contribute to future developments of the teaching programme for undergraduate students. Use the Supplement for Undergraduate Medical and Dental Education (SUMDE) for the purpose for which it was intended i.e. to offset the cost to the practice of supporting the teaching of medical undergraduates. Notify the Centre for Medical Education of absent or problem students as soon as possible. The Practice may request a student to leave the Practice without notice, where that student's behaviour is considered unacceptable. The Practice must notify the relevant Module Coordinator in the Centre for Medical Education immediately with details of the problem(s). Participate in preparatory, introductory and examination sessions organised by the Centre for Medical Education. Maintain well-organised and up-to-date patient r...
Practice Obligations. (a) The Practice must provide all reasonable assistance to WAPHA and its Personnel to enable the installation of the Software, to the extent that the Software is compatible with the Practice’s information technology systems (b) The Practice must comply with all Software licence terms and conditions as further set out in the particulars schedule.
Practice Obligations. The primary goal in this endeavor is to provide and reestablish the Doctor/Patient relationship in healthcare. Additionally, we would like to focus on encouraging you in daily activity and making healthy lifestyle choices. BRAND NEW MED feels that patient and physician should interact and learn together. If you feel that is not accomplished and BRAND-NEW MED is not suitable for you, please notify use immediately and we will make every effort to assist you in transferring your care to a qualified medical practitioner of your choosing.
Practice Obligations. Practice will complete no later than September 30, 2021 the following as part of the Tool Pilot Study: 2.1.1. Community and site profile information; 2.1.2. Site self-assessment tool, which will include completion of questions to facilitate the following: 2.1.2.1. Performance self-assessment; and 2.1.2.2. Identification of opportunities for performance and quality improvement; and 2.1.3. Feedback survey.
Practice Obligations. (a) The Practice must arrange for or undertake the installation of the Software, to the extent that the Software is compatible with the Practice’s information technology systems. (b) The Practice must comply with all Software licence terms and conditions set out in the ▇▇▇▇.
Practice Obligations. (a) The Practice must arrange for or undertake the installation of the Software, to the extent that the Software is compatible with the Practice’s information technology systems. (b) The Practice must comply with all Software licence terms and conditions set out in the EULA.
Practice Obligations. The PRACTICE represents and warrants the following: A. PRACTICE is in compliance with local, state, and federal laws, rules, and regulations governing the ordering, use, dispensing, prescribing and administration of all Products, including Office Use Products and Controlled Products, applicable in the jurisdiction in which the PRACTICE is located; B. All Products purchased from COVETRUS that are dispensed or administered to patients are clearly recorded in the patient’s medical records, including the lot number and beyond-use date of the Office Use Product; and C. Controlled Products purchased from COVETRUS for office use dispensing will only be administered and dispensed pursuant to applicable state Board of Pharmacy rules, state statutes, and federal DEA rules and regulations.
Practice Obligations. Practice will complete the following as part of the Training Pilot Study: 2.1.1. A demographic questionnaire for all participating staff; 2.1.2. Implicit bias training program, which will include the following components: 2.1.2.1. Completion of five (5) virtual learning modules; 2.1.2.2. Participation in one (2) two-hour virtual workshop; and 2.1.2.3. Possible participation in chart-stimulated recall interview and exercise (if randomly selected); 2.1.3. Evaluation surveys (at time of virtual convening and 6-weeks post-convening).
Practice Obligations 

Related to Practice Obligations

  • Licensee Obligations 3.1 The Licensee is responsible for the installation, operation and maintenance of telecommunication lines, equipment, software and other arrangements necessary for the Licensee to receive the Licensed Data from the LME. 3.2 The Licensee shall comply with the terms of any notified and commercially reasonable policy issued by the LME regarding the use of LME Data, including where applicable, any requirements to report to the LME and/or pay fees to the LME in respect of certain transactions undertaken by the Licensee using LME Data, or as otherwise required under the terms of such policy. 3.3 The Licensee shall procure and ensure the Licensee Personnel's compliance with the terms of this Agreement, and shall be entirely liable and responsible for any non-compliance and loss relating to such non-compliance (such being considered a breach by the Licensee).

  • Diligence Obligations (a) AstraZeneca shall use Commercially Reasonable Efforts at its own cost and expense (i) to Develop a Licensed Product and to seek Regulatory Approval for such Licensed Product for use in humans in each of the Major Markets, (ii) Manufacture or have Manufactured Licensed Compound and Licensed Product for use in the Development and Commercialization thereof, and (iii) to Commercialize a Licensed Product for use in humans in each of the Major Markets. AstraZeneca shall perform, or cause its Affiliates or Third Party contractors to perform, its responsibilities under this Agreement, and Ardelyx shall perform, or cause its Affiliates or Third Party contractors to perform the Assigned Activities, in each case, in compliance with this Agreement, all Applicable Laws, applicable FDA (or foreign equivalent) requirements, including, without limitation, then-current GLP, GCP and GMP. For the avoidance of doubt, AstraZeneca shall not be obligated to obtain Regulatory Approvals for, or Commercialize, more than one Licensed Product for use in humans in any Major Market. Further, Ardelyx acknowledges and agrees that nothing in this Section 4.4 is intended, or shall be construed, to require AstraZeneca to Develop or Commercialize a specific Licensed Product. In the event that AstraZeneca decides to discontinue the Development or Commercialization of a [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Licensed Product in favor of another Licensed Product, its obligations under this Section 4.4 shall cease with respect to such initial Licensed Product in favor of such other Licensed Product. AstraZeneca shall have no other obligation, express or implied, to Exploit the Licensed Products. (b) If Ardelyx at any time believes that AstraZeneca may be in material breach of its obligations under Section 4.4(a), then Ardelyx may exercise its rights under Section 16.2(a) or proceed directly to exercise its rights under Section 14.2(a) (subject to the provisions set forth therein), at Ardelyx’s sole discretion.

  • Insurance Obligations Borrower fails to promptly perform or comply with any of the covenants contained in the Loan Documents with respect to maintaining insurance, including the covenants contained in Section 4.4.

  • Surety Obligations No Borrower or Subsidiary is obligated as surety or indemnitor under any bond or other contract that assures payment or performance of any obligation of any Person, except as permitted hereunder.

  • Maintenance Obligations Local Agency shall maintain and operate the Work constructed under this Agreement at its own cost and expense during their useful life, in a manner satisfactory to the State and FHWA. Local Agency shall conduct such maintenance and operations in accordance with all applicable statutes, ordinances, and regulations pertaining to maintaining such improvements. The State and FHWA may make periodic inspections to verify that such improvements are being adequately maintained.